1 December 2001 in Neuroscience Research
1 June 2001 in British Journal of Pharmacology
Prostaglandin E2 (PGE2) is known to be the principal pro‐inflammatory prostanoid and play an important role in nociception. To identify PGE receptor (EP) subtypes that mediate pain responses to noxious and innocuous stimuli, we studied them by use of EP1 and EP3 knockout (EP1−/− and EP3−/−) mice. PGE2 could induce mechanical allodynia in EP1+/+, EP3+/+ and EP3−/− mice, but not in EP1−/− mice. N‐methyl‐D‐aspartate (NMDA), the substrate of nitric oxide (NO) synthase L‐arginine, or the NO donor sodium nitroprusside administered intrathecal (i.t.) could induce allodynia in EP3−/− and EP1−/− mice. Activation of EP1 receptors appears to be upstream, rather than downstream, of NMDA receptor activation and NO production in the PGE2‐induced allodynia. Although PGE2 produced thermal hyperalgesia over a wide range of dosages from 50 pg to 0.5 μg kg−1 in EP3+/+ mice, it showed a monophasic hyperalgesic action at 5 ng kg−1 or higher doses in EP3−/− mice. The selective EP3 agonist, ONO‐AE‐248, induced hyperalgesia at 500 pg kg−1 in EP3+/+ mice, but not in EP3−/− mice. Saline‐injected EP1−/− mice showed hyperalgesia, which was reversed by i.t. PGE2 in a dose‐dependent manner. There was no significant difference in the formalin‐induced behaviours between EP1−/− or EP3−/− mice and the cognate wild‐type mice. These results demonstrate that spinal EP1 receptors are involved in the PGE2‐induced allodynia and that spinal EP3 receptors are involved in the hyperalgesia induced by low doses of PGE2. However, the formalin‐induced pain cannot be ascribed to a single EP receptor subtype EP1 or EP3. British Journal of Pharmacology (2001) 133, 438–444; doi:10.1038/sj.bjp.0704092
27 September 2005 in European Journal of Neuroscience
1 February 2000 in Genes to Cells
Background: 20α‐Hydroxysteroid dehydrogenase (HSD) is a member of the aldo‐keto reductase (AKR) superfamily and catalyses the reaction of progesterone to the inactive form 20α‐hydroxyprogesterone. Progesterone plays an important role in the maintenance of pregnancy, and, in rodents, plasma progesterone levels decrease abruptly just before parturition. The induction of 20α‐HSD is thought to be responsible for the decrease in plasma progesterone at term. High homology between human 20α‐HSD [AKR 1C1] cDNA with other AKRs had caused difficulty in gene isolation and expression analysis. Thus, the metabolism of progesterone in the human reproductive system remained unclear.Results: By hybridization with rat 20α‐HSD [AKR 1C8] cDNA and high‐stringency polymerase chain reaction (PCR) with gene‐specific primers, we were able to isolate the human 20α‐HSD, bile acid‐binding protein (BABP) [AKR 1C2], prostaglandin F synthase (PGFS) [AKR 1C3], and dihydrodiol dehydrogenase (DD) 4 [AKR 1C4] genes. These genes had similar exon‐intron organizations and shared a high homology. The four recombinant enzymes encoded by these genes showed distinct substrate specificity. By reverse transcription‐PCR analysis, human 20α‐HSD, BABP and PGFS mRNAs were expressed ubiquitously, while DD4 mRNA was restricted to the liver. Promoter activities of the 20α‐HSD, BABP and PGFS genes were high, both in ovarian granulosa cells and hepatocytes. Radiation hybridization analysis revealed that all these genes were located close together in chromosome 10.Conclusion: The human gene encoding for the progesterone‐metabolizing enzyme 20α‐HSD in the female reproductive system was cloned, and its expression and gene localization were elucidated. BABP, PGFS and DD4 genes, which were highly homologous to the 20α‐HSD gene, were also cloned, and their structure and function were characterized.
30 November 1999 in FEBS Letters
TSToshiko Suzuki-Yamamoto
+1
1 May 1997 in British Journal of Pharmacology
Intrathecal (i.t.) administration of nociceptin and high doses of morphine induced allodynia in response to innocuous tactile stimuli, and i.t. nociceptin evoked hyperalgesia in response to noxious thermal stimuli in conscious mice. Here we have characterized the nociceptin‐induced allodynia and compared it with the morphine‐induced allodynia and the nociceptin‐evoked hyperalgesia. Nociceptin‐induced allodynia was evoked by the first stimulus 5 min after i.t. injection, reached a maximum at 10 min, and continued for a 50 min experimental period. Dose‐dependency of the allodynia showed a bell‐shaped pattern from 50 pg to 5 ng kg−1, and the maximum effect was observed at 2.5 ng kg−1. Morphine‐induced allodynia reached the maximum effect at 15 min and declined progressively until cessation by 40–50 min. The dose‐response curve showed a bell‐shaped pattern, similar to that induced by nociceptin, with a maximum effect at 0.5 mg kg−1, five orders of magnitude higher than that of nociceptin. The allodynia evoked by nociceptin and morphine were dose‐dependently blocked by glycine, D(−)‐2‐amino‐5‐phosphonovaleric acid (D‐AP5, an N‐methyl‐D‐aspartate (NMDA) receptor antagonist), γ‐D‐glutamylaminomethyl sulphonic acid (GAMS, a non‐NMDA receptor antagonist) and methylene blue (a soluble guanylate cyclase inhibitor), but were not affected by muscimol (a γ‐aminobutyric acidA (GABAA) receptor agonist) and baclofen (a GABAB receptor agonist). Morphine did not inhibit forskolin‐stimulated cyclicAMP formation in cultured cells expressing the nociceptin receptor. Nociceptin‐induced hyperalgesia was evoked 10–15 min after i.t. injection. Nociceptin produced a monophasic hyperalgesic action over a wide range of doses from 5 fg to 50 ng kg−1. The nociceptin‐induced hyperalgesia was blocked by glycine only among the agents examined. None of the pain responses evoked by nociceptin and morphine were blocked by naloxone. These results demonstrate that, whereas the mechanisms of the nociceptin‐induced allodynia and hyperalgesia are evidently distinct, they involve a common neurochemical event beginning with the disinhibition of the inhibitory glycinergic response. Morphine may induce allodynia through a pathway common to nociceptin, but the nociceptin receptor does not mediate the action of high doses of morphine.